Veeva Announces Collaboration with Global Biotech to Further Accelerate Clinical Trial Innovation
Veeva Systems (NYSE:VEEV) has announced a strategic collaboration with Amgen to enhance clinical trial innovation. Amgen will implement the Veeva Clinical Platform to optimize their clinical trial processes and accelerate drug development for serious diseases.
The collaboration includes implementation and change management support from Veeva Business Consulting. Amgen's CIO Scott Skellenger highlighted that this partnership aims to unlock new capabilities for end-to-end trial operations, while Veeva Development Cloud President Jim Reilly emphasized the platform's role in speeding up drug delivery through standardized and connected processes.
Veeva Systems (NYSE:VEEV) ha annunciato una collaborazione strategica con Amgen per potenziare l'innovazione nelle sperimentazioni cliniche. Amgen adotter脿 la Veeva Clinical Platform per ottimizzare i processi dei trial clinici e accelerare lo sviluppo di farmaci per malattie gravi.
La collaborazione prevede supporto all'implementazione e alla gestione del cambiamento da parte di Veeva Business Consulting. Scott Skellenger, CIO di Amgen, ha sottolineato che la partnership mira a sbloccare nuove capacit脿 per operazioni di trial end-to-end, mentre Jim Reilly, Presidente di Veeva Development Cloud, ha evidenziato il ruolo della piattaforma nell'accelerare la consegna dei farmaci tramite processi standardizzati e connessi.
Veeva Systems (NYSE:VEEV) ha anunciado una colaboraci贸n estrat茅gica con Amgen para impulsar la innovaci贸n en ensayos cl铆nicos. Amgen implementar谩 la Veeva Clinical Platform para optimizar sus procesos de ensayos cl铆nicos y acelerar el desarrollo de medicamentos para enfermedades graves.
La colaboraci贸n incluye apoyo en implementaci贸n y gesti贸n del cambio por parte de Veeva Business Consulting. Scott Skellenger, CIO de Amgen, destac贸 que la alianza pretende desbloquear nuevas capacidades para operaciones de ensayos de extremo a extremo, mientras que Jim Reilly, presidente de Veeva Development Cloud, subray贸 el papel de la plataforma en acelerar la entrega de medicamentos mediante procesos estandarizados y conectados.
Veeva Systems (NYSE:VEEV)電� 鞛勳儊鞁滍棙 順侅嫚 臧曧檾毳� 鞙勴暣 Amgen瓿� 鞝勲灥鞝� 順戨牓鞚� 氚滍憸頄堨姷雼堧嫟. Amgen鞚� 鞛勳儊鞁滍棙 頂勲靹胳姢毳� 斓滌爜頇旐晿瓿� 欷戩 歆堩櫂 旃橂鞝� 臧滊皽鞚� 臧�靻嶍檾頃橁赴 鞙勴暣 Veeva Clinical Platform鞚� 霃勳瀰頃� 鞓堨爼鞛呺媹雼�.
鞚措矆 順戨牓鞐愲姅 Veeva Business Consulting鞚� 霃勳瀰 氚� 氤�頇旉磤毽� 歆�鞗愳澊 韽暔霅╇媹雼�. Amgen鞚� CIO 鞀れ涧 鞀れ紙霠岇爛電� 鞚� 韺岉姼雱堨嫮鞚� 鞐旊摐韴棓霌�(End-to-End) 鞁滍棙 鞖挫榿鞚� 靸堧鞖� 鞐焿鞚� 鞐挫柎欷� 瓴冹澊霛缄碃 臧曥“頄堨溂氅�, Veeva Development Cloud鞚� 靷灔 歆� 毽措Μ電� 響滌頇旊悩瓿� 鞐瓣舶霅� 頂勲靹胳姢毳� 韱淀暣 鞚橃暯頀� 鞝滉车鞚� 臧�靻嶍檾頃橂姅 頂岆灚韽检潣 鞐暊鞚� 臧曥“頄堨姷雼堧嫟.
Veeva Systems (NYSE:VEEV) a annonc茅 une collaboration strat茅gique avec Amgen pour renforcer l'innovation dans les essais cliniques. Amgen mettra en 艙uvre la Veeva Clinical Platform afin d'optimiser ses processus d'essais cliniques et d'acc茅l茅rer le d茅veloppement de m茅dicaments pour les maladies graves.
La collaboration comprend un soutien 脿 la mise en 艙uvre et 脿 la gestion du changement de la part de Veeva Business Consulting. Scott Skellenger, CIO d'Amgen, a soulign茅 que ce partenariat vise 脿 lib茅rer de nouvelles capacit茅s pour les op茅rations d'essais de bout en bout, tandis que Jim Reilly, pr茅sident de Veeva Development Cloud, a insist茅 sur le r么le de la plateforme pour acc茅l茅rer la mise sur le march茅 des m茅dicaments gr芒ce 脿 des processus standardis茅s et connect茅s.
Veeva Systems (NYSE:VEEV) hat eine strategische Zusammenarbeit mit Amgen angek眉ndigt, um Innovationen in klinischen Studien voranzutreiben. Amgen wird die Veeva Clinical Platform einf眉hren, um seine Prozesse in klinischen Studien zu optimieren und die Entwicklung von Arzneimitteln f眉r schwere Erkrankungen zu beschleunigen.
Die Zusammenarbeit umfasst Implementierungs- und Change-Management-Unterst眉tzung durch Veeva Business Consulting. Scott Skellenger, CIO von Amgen, betonte, dass die Partnerschaft neue F盲higkeiten f眉r End-to-End-Studienoperationen freisetzen soll, w盲hrend Jim Reilly, Pr盲sident von Veeva Development Cloud, die Rolle der Plattform bei der Beschleunigung der Medikamentenzulieferung durch standardisierte und vernetzte Prozesse hervorhob.
- Partnership with major biotech company Amgen strengthens Veeva's market position
- Expansion of Veeva Clinical Platform adoption in the biotechnology sector
- Additional consulting services revenue through implementation support
- None.
"In collaboration with Veeva, we're leveraging advanced technology to unlock new capabilities for our end-to-end trial operations which are expected to further strengthen our ability to bring innovative treatments to patients with speed and scale," said Scott Skellenger, senior vice president and chief information officer at Amgen.
"We're excited to help Amgen further advance clinical development. Veeva Clinical Platform will provide the backbone for standard and connected processes that can speed the delivery of life-saving drugs to patients in need," said Jim Reilly, president of Veeva Development Cloud.
As part of the collaboration, will support Amgen through implementation and change management.
About Veeva Clinical Platform
Veeva Clinical Platform is a complete and connected platform across clinical operations and data applications. This end-to-end platform includes CTMS, EDC, clinical workbench (CDB), RTSM, eCOA, eTMF, Site Connect, Study Training, and more. Connected products streamline clinical trials from study start-up to close and automate a connected data flow. To learn more about Veeva Clinical Platform, visit .
About Veeva Systems
Veeva delivers the industry cloud for life sciences with software, data, and business consulting. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,500 customers, ranging from the world's largest biopharmaceutical companies to emerging biotechs. As a , Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit .
Veeva Forward-looking Statements
This release contains forward-looking statements regarding Veeva's products and services and the expected results or benefits from use of our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-Q for the period ended April 30, 2025, which you can find 听(a summary of risks which may impact our business can be found on pages 32 and 33), and in our subsequent SEC filings, which you can access at .
Contact:
Deivis Mercado
Veeva Systems
925-226-8821
[email protected]听
View original content to download multimedia:
SOURCE Veeva Systems
FAQ
What is the new collaboration between Veeva Systems (NYSE:VEEV) and Amgen?
How will the Veeva Clinical Platform benefit Amgen's operations?
What support services is Veeva providing to Amgen in this collaboration?
Who are the key executives involved in the Veeva-Amgen collaboration?
